Peptide Delivery
GLP-1 and Peptide Microneedle Product Development
How target dose, loading space, stability and evaluation strategy shape peptide and GLP-1 microneedle development.
Why does dose capacity come first?
Patch area, needle number, needle volume, payload location and active fraction jointly limit theoretical loading. If the requested dose is not compatible with the proposed array, changes to area, structure or product concept may be needed before optimization work begins.
Which stability stresses matter?
Peptides may be sensitive to temperature, moisture, interfaces, shear and excipient environment. Development should consider content, activity where appropriate, related substances, appearance and storage stability through the actual proposed process.
How should release and delivery be evaluated?
In-vitro release, skin permeation or intradermal delivery models can support comparative formulation and structure decisions. Their relevance depends on a justified method and tested conditions; they do not replace required nonclinical or clinical evidence.
How should the program progress?
A staged program links dose and stability findings to formulation selection, process window studies, analytics, packaging and scale-up. This prevents a formulation that works at bench scale from being treated as production-ready without evidence.
Development comparison
| Constraint | Question to answer |
|---|---|
| Dose | Can the target dose fit within a practical patch area and structure? |
| Stability | Does activity remain acceptable through process and storage conditions? |
| Evaluation | Which model can discriminate among the candidate designs? |
Frequently asked questions
Are GLP-1 and other peptides evaluated in the same way?
They share dose and stability considerations, but each active needs product-specific analytical and formulation work.
Can a higher active fraction solve a dose constraint?
It may change mechanical performance, stability and manufacturability, so it must be assessed as part of the full design.
Does an in-vitro result predict clinical performance?
It can support a development decision but cannot by itself establish clinical performance.
Related content
References
- ICH Q5C: Stability Testing of Biotechnological/Biological Products.
- CASMN peptide and sustained-release microneedle research materials.
Published by CASMN — Beijing CAS Microneedle Technology Co., Ltd.